Solid Organ Transplant Immunosuppressant Market to 2018 - Limited Availability of Donors Drives Improvements in Organ Procurement and Preservation Methods

GBI Research, the leading business intelligence provider, has released its latest research, “Solid Organ Transplant Immunosuppressant Market to 2018 - Limited Availability of Donors Drives Improvements in Organ Procurement and Preservation Methods”, which provides insight into the global solid organ transplant immunosuppressant drug market until 2018. The report provides an in-depth analysis of the following five transplant areas: heart, lung, pancreas, liver and kidney. It also details immunosuppressant drug markets in the following key regions: the US, the top five countries of Europe and Japan. The report also includes details about immunosuppressant drug R&D pipelines.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.

GBI Research analysis shows that the global market for immunosuppressant drugs used in transplants is projected to increase at a compound annual growth rate (CAGR) of 6.7% from 2004–2010. The market is forecast to grow at a CAGR of 6.1% from 2010–2018, to reach a value of $5.6 billion in 2018. GBI Research analysis found the R&D pipeline for the immunosuppressant drug market to be moderate. The leading companies in this market, F. Hoffman La Roche, Novartis AG, Genzyme Corporation and Astellas Pharma Inc., are also analyzed in this report.

Report Highlights
GBI Research, the leading business intelligence provider, has released its latest research, “Solid Organ Transplant Immunosuppressant Market to 2018 - Limited Availability of Donors Drives Improvements in Organ Procurement and Preservation Methods”, which provides insight into the global solid organ transplant immunosuppressant drug market until 2018. The report provides an in-depth analysis of the following five transplant areas: heart, lung, pancreas, liver and kidney. It also provides information in the immunosuppressant drug markets in the following key regions: the US, the top five countries of Europe and Japan. The report also includes details about immunosuppressant drug R&D pipelines.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The Global Immunosuppressant Drugs Market will Grow Steadily with Few Promising Products in the Pipeline

The immunosuppressant drugs market is a steadily growing market and the growth rate is expected to remain the steady in the forecast period too. Lack of innovative pipeline implies that market is unlikely to witness sharp growth. Existing leading immunosuppressant drugs are undergoing lifecycle management projects for new indications.

Limited Supplies of Organs Drives Procurement and Preservation Techniques

Medical procedures for organ transplants have evolved due to recent advances in organ preservation and procurement techniques. Survival rates have increased steadily for most patients and for both organs and grafts, as these factors alter the probability of a return to normal organ function. Furthermore, innovations in organ preservation techniques allow greater flexibility, which provides more time for complex and interdisciplinary transplant procedures and processes. In addition to this, transportation of an organ between medical centers is now possible, patients can be called in even if they are not hospitalized and there is adequate preparation time for the patient and the surgical team.

Market Share of Immunosuppressant Drugs in Japan is Low Due to Ethical, Religious and Philosophical Barriers

Japan is the smallest market for solid organ transplant immunosuppressive drugs, contributing just 0.8% to the global market share in 2010. This is due to a number of factors, such as the unique views and ideologies of Japanese people regarding death, life, ethics and religion. Another major reason was a failed attempt by Dr. Wada, Japan’s first heart transplant surgeon, while performing heart transplant from a brain-dead patient in 1968. This raised concerns about the evaluation of what constitutes brain-death resulting in a subsequent 30 year ban on cadaveric organ donation in Japan, which halted further developments in organ transplantation.